Consensus Solid Biosciences Inc.

Stocks

SLDB

US83422E2046

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:53:08 2026-10-29 EDT			5-day change	1st Jan Change
6.580 ^USD	+1.54%		+6.30%	+16.67%

10-26	Solid Biosciences Receives EU Orphan Designation for SGT-212 in Friedreich's Ataxia	MT
10-20	Solid Biosciences Inc. Announces Seven Abstracts Accepted For Poster Presentation At The 33rd European Society Of Gene & Cell Therapy Annual Congress	CI

Evolution of the Average Target: Solid Biosciences Inc.

Evolution of the Target Price: Solid Biosciences Inc.

Changes in Analyst Recommendations: Solid Biosciences Inc.

30e2ff705477d24973a51e6c2b.uYdD9wzFn_5cHGeeh0UEP_tCP29-g-DxT9pQD_u18og._PMwgDr13KgxTlLS5DRhUagXVC1NspGGJpYHbJ3Bkcn80QSoOpfutTVqPg~ed34eeda65fc4d6244cc580754cdbd1a

Analysts' recommendations: Solid Biosciences Inc.

10-15	UBS Initiates Solid Biosciences at Buy With $20 Price Target	MT
09-16	Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says	MT
09-16	RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target	MT
08-07	Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating	MT
05-13	Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating	MT
03-20	Guggenheim Initiates Solid Biosciences at Buy With $26 Price Target	MT
03-12	Wedbush Raises Price Target on Solid Biosciences to $17 From $14, Keeps Outperform Rating	MT
12-04	Needham & Co Initiates Coverage on Solid Biosciences With Buy Rating, $16 Price Target	MT
25-08-13	Wedbush Adjusts Price Target on Solid Biosciences to $14 From $17, Maintains Outperform Rating	MT
25-05-19	Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating	MT
25-05-16	Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating	MT
25-02-19	Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating	MT
25-01-08	Truist Initiates Solid Biosciences at Buy With $16 Price Target	MT
24-12-13	Wedbush Initiates Solid Biosciences at Outperform	MT
24-12-13	Wedbush Initiates Solid Biosciences at Outperform With $16 Price Target	MT
24-12-10	JMP Securities Initiates Solid Biosciences at Market Outperform With $15 Price Target	MT
24-08-19	Chardan Adjusts PT on Solid Biosciences to $15 From $6, Updates Thesis Ahead of Data Release for Gene Therapy Candidate SGT-003; Maintains Buy Rating	MT
24-07-15	Solid Biosciences Shares Rise After JPMorgan Upgrade	MT
24-07-15	JPMorgan Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $15 From $10	MT
24-06-24	Leerink Partners Upgrades Solid Biosciences to Outperform From Market Perform, Price Target is $12	MT
24-03-28	William Blair Starts Solid Biosciences With Outperform Rating	MT
24-03-18	Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating	MT
24-03-15	Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target	MT
24-03-14	Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8	MT
24-03-11	HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SOLID BIOSCIENCES INC.					+188.8%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+38.75%
	Weighted average by Cap.					+23.00%